Zalfermin
Alternative Names: NN 9500; NN9499; NNC-0194-0499Latest Information Update: 07 Jun 2024
At a glance
- Originator Novo Nordisk
- Class Drug withdrawal therapies; Hepatoprotectants; Obesity therapies
- Mechanism of Action Fibroblast growth factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis; Substance-related disorders
- Phase I Non-alcoholic fatty liver disease
- No development reported Obesity
Most Recent Events
- 20 May 2024 Phase-II clinical trials in Substance-related disorders (Combination therapy) in Australia, USA (SC) NCT06409130)
- 20 May 2024 Phase-II clinical trials in Substance-related disorders (Monotherapy) in Australia, USA (SC) (NCT06409130)
- 10 May 2024 Novo Nordisk plans a phase II trial for Alcohol liver disorders (Monotherapy, Combination therapy) in Australia, Bulgaria, Canada, Czech Republic, Denmark, France, Germany, Greece, Italy, Japan, Multinational, Netherlands, Poland, Spain, USA (SC) in May 2024 (NCT06409130)